Peer Exchange

Value-based Considerations of CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer

Patient Journey and Development of Metastatic Breast Cancer
Patient Journey and Development of Metastatic Breast Cancer
Patient, Advocate, and Payer on Value-Based Care for mBC
Patient, Advocate, and Payer on Value-Based Care for mBC
Provider Perspective on Value-Based Care for mBC
Provider Perspective on Value-Based Care for mBC
Patient Cost Burden for Metastatic Breast Cancer Therapy
Patient Cost Burden for Metastatic Breast Cancer Therapy
Provider Responsibility to Cost Burden for mBC Therapy
Provider Responsibility to Cost Burden for mBC Therapy
Value-Based Care vs Cost of Treatment for mBC
Value-Based Care vs Cost of Treatment for mBC
First-line Therapy for HR-Positive, HER2-Negative mBC
First-line Therapy for HR-Positive, HER2-Negative mBC
Pivotal Studies for CDK4/6 Inhibitors
Pivotal Studies for CDK4/6 Inhibitors
Role of CDK4/6 Inhibitors and Patient Selection
Role of CDK4/6 Inhibitors and Patient Selection
Distinguishing Among the Available CDK4/6 Inhibitors
Distinguishing Among the Available CDK4/6 Inhibitors
Formulary Consideration and Clinical Impact of Cost
Formulary Consideration and Clinical Impact of Cost
Breast Cancer Management: Global Cost of Care
Breast Cancer Management: Global Cost of Care
Defining Episode of Care in Metastatic Disease
Defining Episode of Care in Metastatic Disease
Breast Cancer Pathway Guidelines for Practitioners
Breast Cancer Pathway Guidelines for Practitioners
Payer Approval for Frontline Options: Restrictive or Broad?
Payer Approval for Frontline Options: Restrictive or Broad?

Quantifying the Potential Impact of SGLT-2 Inhibitors in Heart Failure

Pathophysiology of Different Types of Heart Failure
Pathophysiology of Different Types of Heart Failure
Progressive Nature and Associated Risks of Diabetes on HF
Progressive Nature and Associated Risks of Diabetes on HF
Cost and Utilization Profile for a Patient With HF
Cost and Utilization Profile for a Patient With HF
Economic Burden of Heart Failure and Goals of Treatment
Economic Burden of Heart Failure and Goals of Treatment
Standard of Care in Patients With Heart Failure
Standard of Care in Patients With Heart Failure
Reducing Readmissions Due to Heart Failure
Reducing Readmissions Due to Heart Failure
CV Outcomes Studies With Medications Indicated for Diabetes
CV Outcomes Studies With Medications Indicated for Diabetes
Recent Studies of SGLT-2s in Patients with HFrEF
Recent Studies of SGLT-2s in Patients with HFrEF

Considering Cost Effectiveness in Cardiovascular Risk Reduction

Economic Burden of Cardiovascular Disease
Economic Burden of Cardiovascular Disease
Risk Assessment for Cardiovascular Disease
Risk Assessment for Cardiovascular Disease
LDL Cholesterol Lowering and CV Risk
LDL Cholesterol Lowering and CV Risk
Cardiovascular Risk Management
Cardiovascular Risk Management
Dyslipidemia: Strategies Used to Reduce CV Risk
Dyslipidemia: Strategies Used to Reduce CV Risk
Statin Therapy for LDL Reduction and CV Risk
Statin Therapy for LDL Reduction and CV Risk
Statin Therapy: Risk for Future CV Events
Statin Therapy: Risk for Future CV Events
PCSK9 Inhibitors and CV Risk
PCSK9 Inhibitors and CV Risk
Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
Targeting Triglycerides to Reduce CV Risk
Targeting Triglycerides to Reduce CV Risk
The REDUCE-IT Study and CV Risk
The REDUCE-IT Study and CV Risk
Interim Analysis of EVAPORATE
Interim Analysis of EVAPORATE

Managed Care Consideration for an Emerging Class of Therapy in Anemia of Chronic Kidney Disease

Overview of Chronic Kidney Disease
Overview of Chronic Kidney Disease
Role of Anemia in CKD
Role of Anemia in CKD
Payer Perspective of Anemia in CKD
Payer Perspective of Anemia in CKD
Treatment of Anemia in CKD
Treatment of Anemia in CKD
Standard of Care: Therapeutic Options for Anemia in CKD
Standard of Care: Therapeutic Options for Anemia in CKD
Anemia in CKD: CHOIR and TREAT Trials
Anemia in CKD: CHOIR and TREAT Trials
Economic Burden of Anemia in CKD
Economic Burden of Anemia in CKD
Treatment of Anemia in CKD During COVID-19
Treatment of Anemia in CKD During COVID-19
HIF Stabilizers for Anemia in CKD: Phase 3 Trials
HIF Stabilizers for Anemia in CKD: Phase 3 Trials
HIMALAYAS Trial: Long-Term Cardiovascular Safety Data
HIMALAYAS Trial: Long-Term Cardiovascular Safety Data
HIF Stabilizers: Management of Anemia in CKD
HIF Stabilizers: Management of Anemia in CKD
Payer Perspective of HIF Stabilizers for Anemia in CKD
Payer Perspective of HIF Stabilizers for Anemia in CKD

Patient Management of Chronic Fibrosing Interstitial Lung Disease With Progressive Phenotype

What Is Interstitial Lung Disease?
What Is Interstitial Lung Disease?
Chronic Fibrosing ILD With Progressive Phenotype
Chronic Fibrosing ILD With Progressive Phenotype
Signs of Chronic Fibrosing ILD With Progressive Phenotype
Signs of Chronic Fibrosing ILD With Progressive Phenotype
Chronic Fibrosing ILD: Presentation and Comorbidities
Chronic Fibrosing ILD: Presentation and Comorbidities
How Is Chronic Fibrosing ILD With Progressive Phenotype Diagnosed?
How Is Chronic Fibrosing ILD With Progressive Phenotype Diagnosed?
Who Identifies and Manages Progressive Chronic Fibrosing ILD?
Who Identifies and Manages Progressive Chronic Fibrosing ILD?
Early Identification of Progressive Chronic Fibrosing ILD
Early Identification of Progressive Chronic Fibrosing ILD
Progressive Chronic Fibrosing ILD: Patient's Perspective
Progressive Chronic Fibrosing ILD: Patient's Perspective
Chronic Fibrosing ILD With Progressive Phenotype: Economic Burden
Chronic Fibrosing ILD With Progressive Phenotype: Economic Burden
Chronic Fibrosing ILD With Progressive Phenotype: Clinical Burden
Chronic Fibrosing ILD With Progressive Phenotype: Clinical Burden
Lack of Guidance in Progressive Chronic Fibrosing ILD
Lack of Guidance in Progressive Chronic Fibrosing ILD
Chronic Fibrosing ILD With Progressive Phenotype: Patient Education
Chronic Fibrosing ILD With Progressive Phenotype: Patient Education
Goals of Treating Chronic Fibrosing ILD With Progressive Phenotype
Goals of Treating Chronic Fibrosing ILD With Progressive Phenotype
Past Management of Chronic Fibrosing ILD
Past Management of Chronic Fibrosing ILD
Progressive Chronic Fibrosing ILD: Antifibrotic Agents
Progressive Chronic Fibrosing ILD: Antifibrotic Agents
Challenges of Chronic Fibrosing ILD With Progressive Phenotype
Challenges of Chronic Fibrosing ILD With Progressive Phenotype
Progressive Chronic Fibrosing ILD: Multidisciplinary Care
Progressive Chronic Fibrosing ILD: Multidisciplinary Care
Unmet Needs in Chronic Fibrosing ILD With Progressive Phenotype
Unmet Needs in Chronic Fibrosing ILD With Progressive Phenotype

Expanding Treatment Options for Metastatic Breast Cancer

Treatment After Progression on CDK 4/6i in mBC
Treatment After Progression on CDK 4/6i in mBC
SOLAR-1 Trial in Metastatic Breast Cancer
SOLAR-1 Trial in Metastatic Breast Cancer
Payer Perspective of Coverage on Cancer Therapies
Payer Perspective of Coverage on Cancer Therapies
Payer Coverage on Repeat Biopsy in mBC
Payer Coverage on Repeat Biopsy in mBC